InflaRx (IFRX) Finished Goods (2023 - 2025)
InflaRx (IFRX) posted Finished Goods of $60874.5 for Q2 2025, up 0.6% sequentially from $60511.4 in Q4 2024, and up 21.41% YoY from $50138.8 in Q2 2024.
InflaRx (IFRX) Finished Goods (2023 - 2025) Analysis & Trends
InflaRx has reported Finished Goods for 3 years, with the latest figure at $60874.5 in Q2 2025.
- Quarterly Finished Goods rose 21.41% year-over-year to $60874.5 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $60874.5 (up 21.41% YoY) and the FY2024 annual result came in at $61289.6, down 82.83% from the prior year.
- Finished Goods improved to $60874.5 in Q2 2025 per IFRX's latest filing, from $60511.4 in the prior quarter.
- Over five years, Finished Goods peaked at $286.4 billion in Q3 2023 and troughed at $50138.8 in Q2 2024.
- A 3-year average of $57.3 billion and a median of $60874.5 in 2025 frame the typical range for Finished Goods.
- The sharpest annual moves came in 2024 and 2025: Finished Goods sank 82.96% in 2024, then grew 21.41% in 2025.
- Over 3 years, Finished Goods stood at $355153.8 in 2023, then tumbled by 82.96% to $60511.4 in 2024, then advanced by 0.6% to $60874.5 in 2025.
- According to Business Quant data, Finished Goods over the past three periods registered $60874.5, $60511.4, and $50138.8 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 60,874.53 |
| Dec 31, 2024 | 60,511.35 |
| Jun 30, 2024 | 50,138.81 |
| Dec 31, 2023 | 355,153.78 |
| Sep 30, 2023 | 286.43 Bn |